ProMark Advantage Metamark Genetics offers ProMark, a proteomic prognostic test that supports decision-making in early-stage prostate cancer. Potential sales opportunity: position ProMark as a companion diagnostic to refine risk stratification, potentially reducing overtreatment and aligning with payer value-based care initiatives.

Urologic Focus The company specializes in urologic oncology diagnostics (prostate and bladder cancers). Selling angle: target urology clinics, pathology labs, and academic centers with workflow integrated proteomic testing that complements existing biopsy and NCCN-guidelines workflows.

ClinicalProteomics Leader in clinical proteomics suggests robust protein-signature based tests. Sales approach: emphasize proprietary protein markers, demonstrated prognostic value, and potential for expanding to additional urologic and cancer indications as data matures.

EconomicValue Recent study indicates cost-effective care when using ProMark versus NCCN risk classification alone. Opportunity: engage payers and HTA bodies by presenting health economic benefits, potential to lower treatment costs, and improved risk-adapted management.

GrowthSignals Revenue in the mid single to low double digits with private backing and a lean team. Sales angle: position as a growth partner with scalable testing services, integration with existing IT and lab infrastructure, and opportunities for strategic collaborations or co-development.